Massive Bio is putting its first strategic AI investment into Rivvi, a Cambridge healthcare technology company built to turn patient conversations into coordinated medical action. The deal pairs Massive Bio’s clinical-trial intelligence with Rivvi’s effort to make sure patients do not disappear somewhere between a promising match and the next phone call.
The investment was announced Tuesday from Las Vegas, with the financial terms not disclosed. According to Voice of Alexandria, Massive Bio described the transaction as its first strategic investment in another AI company.
Cambridge Startup Brings The Patient Outreach Layer
Rivvi’s company profile lists Cambridge, Massachusetts, as its headquarters and says the startup was founded in 2024. The company describes itself as conversational AI infrastructure for healthcare, supporting medication adherence, care-gap closure, chronic-care management, clinical-trial coordination and population-health programs, according to its official LinkedIn profile.
Rivvi’s platform is designed to reconcile fragmented payer, pharmacy and clinical data, then use voice and messaging to reach patients and trigger the next workflow. Its website says the system can surface medication side effects, cost barriers and missed care steps while routing urgent concerns to human teams, without requiring a new electronic medical-record integration; it also lists HIPAA and SOC 2 Type II compliance.
Massive Bio Brings Trial-Matching Evidence
Massive Bio arrives with a more specialized healthcare AI track record, using clinical and biomarker data to identify cancer patients who may qualify for clinical trials. In a prospective evaluation of 3,804 patients, the company reported that its system matched patients to trials four times faster than conventional workflows, reached an F1 score of 0.82 and generated more than 17,000 oncologist-confirmed matches, according to a Massive Bio study announcement.
The proposed combination is meant to connect that matching engine to the less glamorous but essential work that follows. As reported by Voice of Alexandria, Massive Bio’s Reticulum Nexus suite is intended to produce explainable trial matches and prioritized cohorts, while Rivvi’s orchestration tools handle outreach, barrier discovery, scheduling, consent capture and escalation to human staff.
Why The Last Mile Matters In Cancer Trials
Only an estimated 3% to 5% of U.S. adults with cancer enroll in therapeutic clinical trials, a gap that leaves many potential participants outside the research system. Industry coverage from ASCO AI in Oncology describes the operational burden of matching patients to increasingly complex studies, even when relevant trials may exist.
The companies are emphasizing that the technology is meant to support care teams rather than replace them. Rivvi says its AI does not make clinical decisions, while Massive Bio has stressed that clinical judgment remains with clinicians and trial participation remains the patient’s choice.
From Trial Matches To Broader Healthcare Workflows
Massive Bio has been expanding beyond a single trial-search function, unveiling Reticulum Nexus as a broader oncology access platform that connects patients, physicians, research sites and sponsors. The company says the suite includes patient navigation, referral orchestration, real-time signals and clinician-facing intelligence, according to its ASCO 2026 announcement.
Taken together, the investment looks less like a simple chatbot partnership and more like a bet on linking healthcare intelligence to the last mile of patient action. Rivvi’s infrastructure pitch is that conversations should create completed workflows, while Massive Bio’s pitch is that better intelligence should lead to more reachable patients and more usable options.
